Pazopanib HCL intermediates manufacturer
Recently, AstraZeneca announced that its partner, Fanbojin, has been approved by the State Drug Administration (NMPA) for new indications, i.e. Roxadustat (trade name: Erezhuo *) for anemia treatment in non-dialysis dependent chronic kidney disease (NDD CKD). This is the first time that the indications of rosalista have been expanded after it was approved for anemia treatment in dialysis patients with chronic kidney disease on December 17, 2018. As one of the world's first innovative drugs, Rosalos is the first to achieve comprehensive application of dialysis and non-dialysis chronic kidney disease anemia patients in China, bringing a new breakthrough in the treatment of chronic kidney disease in China.
Roxadustat is the world's first oral hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by AstraZeneca and Fairchild. As the first global synchronous research and development, the first class of new drugs in China, Roxadustat has been listed in the major scientific and technological projects of "Major New Drug Creation" in China. At the same time, thanks to the government's strong support for pharmaceutical innovation and the deepening of drug approval reform, Roxadustat has won the priority approval of the China Pharmaceutical Regulatory Commission and is scheduled to be fully listed in China in the second half of 2019.
Chronic kidney disease has become an important public health problem in China. The incidence of chronic kidney disease in Chinese adults is 10.8%, and the number of patients is nearly 120 million. Renal anemia is one of the common complications of chronic kidney disease. The prevalence of renal anemia in dialysis and non-dialysis CKD patients is 98.2% and 52.1%, respectively. According to a survey of anemia in non-dialysis patients in Shanghai, the prevalence rates of anemia in CKD 1-5 patients were 22.4%, 30.0%, 51.1%, 79.2% and 90.2% respectively. The total prevalence rate of anemia in non-dialysis patients was 51.5%, and the treatment rate of anemia was 44.9%, while the standard rate of treatment was only 8.2%(11-12g/dL). The clinical treatment of renal anemia is in great demand.
